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Pediatric multiple sclerosisChildren and adolescents diagnosed with multiple sclerosis rarely accrue physical disability early in their
disease. This could be explained by greater remyelination in children, a capacity that may be lost in adoles-
cence or early adulthood. Magnetization transfer ratio (MTR)MRI can be used to quantify changes inmyelin
in MS. We used serial MTR imaging and longitudinal random effects analysis to quantify recovery of MTR in
acute lesions and to evaluateMTR changes in normal-appearing tissue in 19 adolescentMS patients. Our ob-
jective was to determine whether younger adolescents have a greater capacity for remyelination and
whether this decreases as patients approach adulthood. We detected a signiﬁcant decrease in MTR recovery
between ages 16 and 20 years (p = 0.023), with older subjects approaching typical recovery levels for
adult-onset MS. MTR recovery in acute MS lesions decreases with age in adolescents, suggesting loss of
remyelination capacity. This may be related to the conclusion of primary myelination or other developmen-
tal factors.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Multiple sclerosis (MS) is an autoimmune disease characterized by
the formation of inﬂammatory demyelinating lesions in the central ner-
vous system. Although MS is normally diagnosed in adults, some pa-
tients experience clinical onset before the age of 18 (Banwell et al.,
2007).
Focal MS lesions vary in their degree of myelin loss. Histopathologi-
cal analysis of remyelination in the brain of MS patients is limited, and
most specimens have been obtained from older adults with long-
standing and often secondary progressive MS. Fully demyelinated le-
sions are common in these patients (Miller et al., 1996), but partially
remyelinated “shadow plaques” are also observed (Patrikios et al.,
2006), indicating that the adult brain has some ability to repair myelin.
It has been suggested that remyelination capacity decreases with age
(Fancy et al., 2010; Franklin et al., 2002) in humans and in animal
models of induced CNS demyelination (Hinks and Franklin, 2000;
Ruckh et al., 2012; Shen et al., 2008; Sim et al., 2002).), banwellb@email.chop.edu
. This is an open access article underIf remyelination capacity decreases with age in adults, we would ex-
pect children and adolescents with MS to have an even greater capacity
for remyelination, and some clinical features of pediatric-onset MS sug-
gest that this may be true. Children and adolescents usually recover
completely from their ﬁrst attack (Bigi and Banwell, 2012; Ruggieri
et al., 2004) and rarely accrue physical disability within the ﬁrst
10 years of the disease (Renoux et al., 2007).
In order to investigate myelination as a function of age, as well as
lesional remyelination capacity in vivo, an imaging technique sensitive
to changes in myelin content is needed. Suitable methods include mye-
lin water fraction (MWF), derived from multicomponent T2 mapping;
restricted proton pool size, derived from quantitative magnetization
transfer (qMT) imaging; and magnetization transfer ratio (MTR),
which is a semi-quantitative measurement of magnetization exchange
between free and bound proton pools. We have used an MTR-based
approach in this study because data with the required resolution
for lesion-based analyses can be acquired relatively quickly, an impor-
tant issue for pediatric studies. MTR has been histopathologically vali-
dated as a marker for myelin in both humans and animals and has
excellent quantitative correlation with the Luxol fast blue stain, which
is attracted to lipoproteins in the myelin sheath and is used as a stan-
dard stain for myelin (Barkhof et al., 2003; Chen et al., 2007; Deloire-
Grassin et al., 2000; Dousset et al., 1992; Pike et al., 2000; Schmierer
et al., 2004).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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sudden decrease at the time of lesion formation, followed by partial re-
covery. We have developed anMTR imaging-based technique that uses
longitudinal scanning to identify focal areas of tissue that experience an
acute decrease in MTR (corresponding to demyelination) and quantify
subsequent recovery (remyelination) (Brown et al., 2012). These
“ΔMTR” lesions are distinct from other lesion types normally identiﬁed
in MS, such as hyperintensities on T2-weighted or gadolinium contrast
enhanced scans; because they are identiﬁed on MTR images, they are
more speciﬁc to demyelination (Brown et al., 2012). The MTR
timecourse within these lesions can be modeled and produces a statis-
tically powerfulmeasurement of differences inMTR recovery, indicative
of remyelination.
If the capacity for repair of MS lesions is particularly robust
when concurrent with ongoing myelin maturation or other develop-
mental factors, we would expect that adolescent MS patients would
have a greater capacity to repair lesions in early adolescence than in
late adolescence/early adulthood, as primary myelination reaches
completion.
We quantify changes in lesional MTR in a cohort of adolescents with
MS imaged longitudinally frommid-adolescence to early adulthood.We
hypothesize that MS lesion remyelination capacity, measured by MTR
recovery, (1) decreases rapidly with age in adolescents with MS, and
(2) in older adolescents, reaches a level comparable to that seen in
adults with MS.
2. Material and methods
2.1. Subjects
All subjects were selected from a single site (The Hospital for Sick
Children, Toronto), and all were imaged on the same 1.5 TMRI scanner.
Subjects were selected from two studies: our national study of acquired
demyelination in Canadian children (Banwell et al., 2011),and from a
serial MRI and neurocognitive study of pediatric MS (Till et al., 2011).
Subjects selected from the national Canadian study were imaged
from the ﬁrst attack, at 3, 6 and 12 months, and annually. Subjects en-
rolled in the MRI and neurocognitive study were enrolled at variable
timepoints post-MS onset and were imaged two to four times,
12 months apart.
For selection for the present analysis, subjects were required (1) to
have a diagnosis of relapsing–remitting MS according to the McDonald
2005 criteria (Polman et al., 2005) — the 2010 McDonald criteria were
not available at the time of diagnosis for many of the patients; (2) to
have serial scans with high quality MTR imaging, and for these scans
to include at least one scan prior to detection of a new lesion, one scan
with a new lesion, and one scan at least 6 months after the scan with
the new lesion; (3) to be between 15 and 21 years of age at the time
of the MRI scan with new lesions; (4) to have their new lesion scan at
least 6 months after their incident attack; (5) to have all scans selected
to bemore than 30 days from a clinical relapse or any corticosteroid ex-
posure; and (6) to either be free of any immunomodulatory therapy or
treated with one of the current disease-modifying therapies (DMTs):
glatiramer acetate (GA; Copaxone, Teva Pharmaceutical Industries,
Petah Tiqva, Israel), or one of two formulations of interferon β-1a
(IFN-R; subcutaneous Rebif, Merck Serono International, Geneva,
Switzerland or IFN-A; intramuscular Avonex, Biogen, Cambridge,
USA). No patient was treated with interferon-beta 1b so we did not in-
clude this in our criteria. Very few pediatric MS patients were exposed
to other therapies, such as natalizumab or cyclophosphamide, and any
such patients were excluded.
2.2. Imaging
Images were acquired on a single 1.5 T GE TwinSpeed Excite 12.0
scanner (GE Medical Systems, Milwaukee, USA). Sequences obtainedincluded: T1-weighted (T1; sagittal SPGR, TR = 22 ms, TE = 8 ms,
1.5 × 1 × 1 mm, ﬂip angle 30°), T2-weighted and proton density-
weighted (T2, PD; dual echo axial FSE, TR = 3500 ms, TE = 15, 63 ms,
1 × 1 × 2 mm), and magnetization transfer images (axial SPGR, TR =
27 ms, TE = 4 ms, 1.5 × 1.5 × 1.5 mm, ﬂip angle 12°) with (MTON)
and without (MTOFF) a magnetization transfer pulse (8 ms Fermi).
Voxel sizes are all right/left × anterior/posterior × superior/inferior.
An adult male volunteer was also scanned at intervals on the same
scanner with the same protocol as a “living phantom.” MTR images
were calculated for each subject at each timepoint using the formula
MTR ¼ 100  MTOFF−MTONMTOFF and normalized using the living phantom data,
according to the procedure in Brown et al. (2012). This normalization
process maps raw MTR measurements onto a calibrated scale, where
normal white matter (WM), as deﬁned by the living phantom, has a
value of 1 and normal gray matter (GM) has a value of 0, and reduces
inter-scanner variability to below the level of inter-subject variability
(Brown et al., 2011), as well as corrects potential longitudinal changes
in measured MTR on a single scanner. Although MTR measurements
are unitless, wewill refer tomeasurements on this scale as being in nor-
malized MTR units (nMU) for clarity.
2.3. Preprocessing
All images for each subject were co-registered (minctracc,
McConnell Brain Imaging Centre, Montreal, Quebec, Canada (Collins et
al., 1994)) and probability maps for WM, GM, cerebrospinal ﬂuid
(CSF) and T2 lesions were constructed using a Bayesian classiﬁer with
the T1, T2 and PD images as input (Francis, 2004). T2 lesion masks
were automatically generated from the T2 lesion probability maps,
reviewed and, if necessary, edited by trained readers. Longitudinally-
consistent high conﬁdence WM and GMmasks (HCWM, HCGM) were
constructed, consisting of tissue identiﬁed as having greater than 85%
probability WM or GM at every timepoint. Finally, de novo ΔMTR lesion
masks were generated as previously described (Brown et al., 2012).
ΔMTR lesionswere segmented fromMTR difference images by identify-
ing focal areas of newly-appearing MTR signal decrease. De novo ΔMTR
lesionswere deﬁned as those occurring in previously normal-appearing
WM.
2.4. Analysis
Each lesion was assigned a unique identiﬁer and regions of interest
(ROIs) corresponding to each lesion were identiﬁed on all scans. MTR
values of voxels within the ROIwere averaged, producing amean lesion
MTR measurement at each timepoint. Together with the elapsed time
relative to the lesion appearance, these data form an MTR timecourse
for the lesion, showing MTR evolution from before lesion formation,
through acute inﬂammation, to post-lesion follow-up. From other data
(Brown et al., 2012) we have observed that MTR values in lesions
change rapidly during the acute inﬂammatory phase, decreasing from
about 1 month before the lesion is observed, recovering partially by
3 months, and then remaining relatively stable in the longer term
(Brown et al., 2012). MTR measurements made during the period of
acute lesion formation could be inﬂuenced by inﬂammation and its res-
olution. For these reasons, only samples acquired outside the acute pe-
riod (deﬁned as 1month prior to 3months after lesion formation) were
included in our statistical models, although all data have been graphed
to illustrate the entire timecourse.
The primary goal of the analysis was to detect changes in the
amount of MTR recovery with age. However, disease duration and
treatment status might be signiﬁcant confounding factors. Since
disease duration and age are correlated longitudinally, these should
not both be factors in the same model. Therefore, we used age at
onset in place of disease duration, which corrects for any effects related
to disease duration, independent of the age at which a new lesion is
observed.
Fig. 1.Histograms of lesion distribution by subject and age. The data exhibited the expected distribution of new lesion countswithmost subjects having only a fewwhile others hadmany.
The number of new lesionswasdistributed approximately uniformly by age except for an increased number around the age of 16;many subjects started diseasemodifying therapy around
this age.
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(GLMM) in R (R Team, 2010) using the lme4 package (Bates et al. 2012)
with the formula:
MTR  ageþ ageAtOnset þ treatment þ recoveryþ recovery : age
þrecovery : age2 þ recovery : treatment þ recovery : ageAtOnset
þ 1 subject=timepointj =lesionð Þ
where “:” indicates an interaction and (1|subject/timepoint/lesion) is a
nested random intercept. The subject3s age at new lesion formation,
age at onset, and treatment at the time of lesion appearance, plus a
dummy variable recovery indicating that the MTR measurement was
taken after the lesion formed, were the main ﬁxed effects; interactions
of recovery with each of age at lesion appearance, treatment, and age
at onset were included. As we expected the remyelinative capacity to
decrease rapidly in adolescence and then stabilize as subjects
approached adulthood, we also included an interaction between age2
and recovery, allowing the rate of change to accelerate or decelerate
with age. The random effects were lesion, nested within timepoint,
within subject. This random effects structure accounts for correlations
between lesions within a subject, lesions appearing at the same
timepoint, and between measurements taken over time in each lesion.
The recovery factormeasures the change inMTR froma stable pre-lesion
value to stable post-lesion value.We expect the recovery to be negative,
indicating that theMTR recovers only partially. The recovery:age and re-
covery:age2 interactions measure changes in the amount of recovery
demonstrated by lesions that appear in subjects at different ages.
Since measurements taken from larger lesions are averaged over more
voxels, these measurements have a lower variance as well as beingTable 1
Subject demographics.
Minimum Median Maximum
Age
(years; at time of lesion appearance)
15.6 17.1 20.1
Age at First Attack (years) 5.3 13.2 16.7
Sex Male: 2 Female: 17
Treatment
(at time of lesion appearance)
No DMT: 3 GA: 12
IFN-A: 6 IFN-R: 5less affected by partial volume effect. The standard error decreases by
the square root of the number of averaged samples, so measurements
were weighted in the model by the square root of the volume of the le-
sion they were taken from.
Age at lesion appearance and age at onset values were “centered” by
subtracting 16 and 13, respectively, so the modeled effects are relative
to a 16 year old subject with an age of onset of 13 years. Centering var-
iables that have a non-zero mean, such as age, is a recommended
modeling practice. In this case it makes explicit that a linear trend is
not being imposed from birth, making interpretation of the results
more straightforward. The ﬁt of the model as a whole was evaluated
by comparing the log-likelihoods of the model and a null model using
a χ2 test. If this “gateway test” was signiﬁcant, individual effects were
evaluated using f-tests, with denominator degrees of freedomestimated
using a Satterthwaite approximation, by the R package MixMod
(Kuznetsova and Brockhoff, 2012). This methodology eliminates theFig. 2. MTR timecourses in de novo ΔMTR lesions. Light lines indicate individual
timecourses while heavy lines are estimates generated from a model. Shaded areas indi-
cate 95% conﬁdence regions. Lesions showedMTR decreasing at the time of lesion forma-
tion (time 0), then recovering partially afterward. The recovery value is the difference
between the stable post-lesion value and the stable pre-lesion value. Sample curves
from the model for an average 16 year old (solid) and a 19 year old (dashed), both with
MS onset at age 13, are shown.
Table 2
Parameter estimates of the statistical model.
Effect Estimate (nMU) Prediction
(nMU, reference subject)
Degrees of freedom f p
Intercept 1.10 1.10 – – –
Age −0.013/year 1.10 1/34 0.00 0.99
Recovery −0.65 0.45 1/480 263 b0.0001
Recovery:age at onset −0.015/year 0.45 1/431 12.8 0.0004
Recovery:age −0.19/year 0.45 1/518 5.18 0.023
Recovery:age2 0.032/year2 0.45 1/504 0.740 0.39
Recovery:treatment (IFN-A) 0.08 0.53 3/463 6.46 0.0003
Recovery:treatment (IFN-R) 0.0067 0.45
Recovery:treatment (GA) −0.23 0.22
Random effects χ2 = 223; p b 0.00001
Lesion Variance = 0.056
Timepoint Variance = 0.000
Subject Variance = 0.040
Residual Variance = 0.066
p N 0.05 using a standard general linear mixed model f-test with denominator degrees of freedom estimated by the Satterthwaite approximation, as discussed in the methods.
240 R.A. Brown et al. / NeuroImage: Clinical 6 (2014) 237–242need for multiple comparisons when examining orthogonal contrasts
within the model. R2 values were produced according to the procedure
suggested by Nakagawa and Schielzeth (2012), where the marginal R2
is the variance explained by the ﬁxed effects alone, and the conditional
R2 is the variance explained by the entire model including random
effects.
Measurements of the post-lesion MTR value have less statistical
power to detect changes in recovery than the pre- to post-lesion differ-
ence (Brown et al., 2012), but may be useful for comparisons when the
pre-lesion MTR values are very different, such as when comparing sub-
jects with short disease duration with those who have long-standing
diffusewhitematter changes. These valueswere calculated by summing
the relevant factors from the model.
3. Results
The ﬁnal dataset included data from 241 new lesions in 19 pediatric-
onset MS patients (2 males, 17 females). Lesions were identiﬁed on 26
unique scans, thus several subjects had new lesions at more than one
timepoint (Fig. 1). Subjects were aged 15.6–20.1 years (mean 17.4, me-
dian 17.1) at the time of lesion appearance and age atﬁrst attack rangedFig. 3. The difference between post- and pre-lesion MTR by age. A recovery value of 0 in-
dicates full post-lesionMTR recovery to baselinewhile negative values indicate partial re-
covery. Circles indicate measured values in individual lesions. Light lines connect mean
values for subjects with new lesions and enough data to measure recovery at multiple
timepoints. The dark line indicates the model prediction for the average subject and the
shaded area is the 95% conﬁdence region. MTR recovery decreases signiﬁcantly with age.from 5.3 to 16.7 years (mean 12.5, median 13.2). Treatments at the time
of lesion appearancewere IFN-R: 5; IFN-A: 6; GA: 12 and noDMT: 3. De-
mographic data are summarized in Table 1.
As illustrated in Fig. 2, an acute decrease in MTR at the time of lesion
formation was noted, followed by partial recovery. Table 2 provides the
results of themodel ﬁt. Themodel ﬁt is signiﬁcantly better than the null
model (p b 0.0001) and achieved amarginal R2 of 0.54 and a conditional
R2 of 0.81. Pre-lesion MTR values had a mean of 1.10 nMU and did not
change signiﬁcantly with age at scan (p= 0.99). New MTR lesions ex-
hibited a signiﬁcant reduction of MTR signal to a post-lesion level of
0.65 nMU (p b 0.0001) in the reference case (age = 16, age at
onset = 13, no DMT). Older age at onset was associated with slightly
poorer recovery (−0.015 nMU/year; p= 0.0004). MTR signal recovery
within lesions decreased signiﬁcantly with increasing age at lesion ap-
pearance (−0.19 nMU/year, p = 0.023). The quadratic term age2 was
positive, but not signiﬁcant (0.032 nMU/year2; p = 0.39). Treatment
with DMTs was also a signiﬁcant factor in recovery (p= 0.0003).
Since the recovery–age relationship is of primary interest and qua-
dratic terms can have large effects on model ﬁts, the model was reﬁt
without the age2 factor, yielding similar results and no change in the
statistical signiﬁcance of any factors. To determine whether our results
were impacted by a small number of subjects with a large number of le-
sions, we ﬁt the model using subject-wise data where values from le-
sions within individual subjects were averaged. Although p-values in
the resulting model were increased due to the effective reduction in
sample size, the model yielded similar results, with no change in signif-
icance except for the recovery:age at onset factor (p= 0.34).
Fig. 3 shows the pre- to post-lesion MTR difference (recovery) as a
function of age at lesion appearance. The round markers indicate mea-
surements in individual lesions. Some subjects had recovery measure-
ments from lesions at more than one timepoint, and these are
indicated by light lines joining the volume-weighted mean recovery
value at each timepoint. Vertical lines connectmeasurements frommul-
tiple new lesions at the same timepoint in individual subjects. A predict-
ed mean curve from the model is shown as a heavy line with shading
indicating the 95% conﬁdence region.
The Prediction column of Table 2 gives predicted MTR values for the
reference case: the predicted post-lesion MTR value for untreated
16 year olds (onset at age 13) was 0.45 nMU while for eighteen year
olds it was 0.13.4. Discussion
We demonstrated an age-related decline in lesional recovery during
adolescence and into early adulthood. The onset of MS during childhood
able A.1
arameter estimates of the subject-wise statistical model.
Effect Estimate (nMU) Degrees of freedom f p
Intercept 1.18 – – –
Age −0.044/year 1/22 0.97 0.33
Recovery −0.75 1/48 24 b0.0001
Recovery:age at onset −0.0075/year 1/66 0.91 0.34
Recovery:age −0.073/year 1/48 4.1 0.049
Recovery:treatment
(IFN-A)
0.23 3/62 3.6 0.018
Recovery:treatment
(IFN-R)
0.037
Recovery:treatment
(GA)
−0.041
Random effects
Subject Variance = 0.20
Residual Variance = 0.76
p b 0.05 on a standard general linear mixed model f-test using denominator degrees of
freedom estimated by a Satterthwaite approximation, as discussed in the methods.
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in the ﬁrst 10 years of disease (Bigi and Banwell, 2012; Boiko et al.,
2002; Renoux et al., 2007, 2008; Yeh et al., 2009a). Although there may
exist several explanations for the preservation of physical function seen
in pediatric MS patients, one possible mechanism could be effective re-
pair of lesions.We and others have shown that the overall lesion burden,
as measured by both T2- and T1-weighted images, is similar in
pediatric- and adult-onset MS (Ghassemi et al., 2008a, b; Yeh et al.,
2009b). Thus, the lower risk of physical disability cannot be attribut-
ed to a lower lesion burden in children and adolescents.We have also
recently shown that pediatric-onset MS patients have lower global
and regional brain volumes, compared to healthy age- and sex-
matched pediatric populations (Aubert-Broche et al., 2011; Kerbrat
et al., 2012), further indicating that pediatric-onset MS patients are
not spared from the injurious pathology that characterizes MS.
Thus, preserved physical functioning in the face of active inﬂamma-
tory disease may relate to improved remyelination within lesions or
potentially to a heightened capacity of pediatric patients to marshal
alternative neural networks (plasticity).
Although we did not have an adult control group acquired on the
same scanner with the same protocol with which to compare, pub-
lished data in adults (Brown et al., 2012) offers a qualitative compar-
ator. We previously report pre-lesion MTR values in adults of about
0.5 nMU, which compares to 1.1 nMU in adolescents in this study;
normal adult WM has a median value of 1.0 nMU. Children and
young adolescents are expected to have slightly higher WM MTR
than normal adults because MTR has been observed to decrease
slightly, at least in males, during adolescence (Perrin et al., 2008).
The very low pre-lesion value observed in adults with MS suggests
that these patients have accumulated considerable diffuse WM
damage.
Post-lesion MTR values in de novo ΔMTR lesions in adults were ap-
proximately 0 nMU (Brown et al., 2012), compared to 0.45 nMU and
0.13 nMU in sixteen and eighteen year olds, respectively. These values
indicate that early adolescents enjoy a heightened capacity for
remyelination compared to late adolescence and adulthood. Adult pa-
tients between 18 and 20 years of age were already demonstrating
post-lesion MTR values comparable to those seen in older adults.
This observation, as well as the positive age2 effect estimated by our
model, is consistent with the hypothesis that young adolescents enjoy
a heightened capacity for remyelination, which is lost as they enter
adulthood.
Reduced remyelinative capacity in late adolescence could be caused
by the loss of factors uniquely associated with brain development,
which are lost at the end of adolescence, or by the same processes
that produce slow decline in adults. Various studies, primarily in ani-
mals, have attempted to identify the causes of adult age-related de-
creases in remyelination. These have observed increasing delays in
(1) colonization of lesions by oligodendrocyte precursor cells (OPCs)
(Sim et al., 2002), (2) OPC differentiation (Sim et al., 2002), (3) up-
regulation of growth factor expression (Hinks and Franklin, 2000)
and (4) macrophage response (Hinks and Franklin, 2000; Ruckh
et al., 2012) with increasing age, as well as inefﬁcient suppression
of OPC differentiation inhibitors (Shen et al., 2008) and decreased ef-
ﬁciency of myelin debris clearance (Gilson and Blakemore, 1993).
Recently, Ruckh et al. used rats with surgically connected circulatory
systems (parabiotically bound partners) to demonstrate that
remyelination in older rats can be improved through the availability
of peripheral macrophages provided by young partners (Ruckh et al.,
2012).
Associations between adolescent brain development andmyelination
are suggested by the observation that white matter volume increases
during adolescence and early adulthood (Aubert-Broche et al., 2013;
Lenroot et al., 2007; Perrin et al., 2008). This may be due to ongoing pri-
marymyelination, whichmight continue into early adulthood, at least in
some brain regions (Benes et al., 1994; LaMantia and Rakic, 1990, 1994).There is also evidence that late adolescent growth in white matter may
be at least partially due to increases in axon caliber (Perrin et al., 2008),
whichmay require active remodeling of the myelin sheath to accommo-
date thickening axons. These processes may be supported by an adoles-
cent brain microenvironment that is also more favorable for robust
remyelination.
The association we observed between older age at disease onset
and poorer recovery is at ﬁrst glance surprising: later onset implies
shorter disease duration for a subject of a given age. Since disease dura-
tion is correlatedwith both age and age at onset, it can be difﬁcult to sep-
arate the effects of these three factors, but it is possible that patients who
develop MS at a younger age may experience delayed development,
retaining remyelination-enhancing developmental factors to an older
age.
We detected a signiﬁcant decrease in MTR recovery in lesions in ad-
olescent MS patients imaged frommid-adolescence to early adulthood.
The heightened reparative capacity in the younger adolescents may, in
part, explain the limited physical disability seen in these patients.
Whether the relative loss of reparative capacity in early adulthood will
render patients at the same risk of disability as adult-onset MS patients
remains to be seen. Further studies of even youngerMS patientswill de-
termine whethermyelin repair is even greater in periods of more active
primary myelination.Conﬂicts of interest
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